2-chloro-N-methyl-5-nitro-aniline | 101513-60-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-chloro-N-methyl-5-nitro-aniline
• 英文别名: 2-chloro-N-methyl-5-nitroaniline；2-chloro-N-methyl-5-nitro-aniline；2-Chlor-N-methyl-5-nitro-anilin；2-chloro-5-nitro-(N-methyl)-aniline
• CAS: 101513-60-4
• 化学式: C₇H₇ClN₂O₂
• 分子量: 186.598
• InChiKey: COAVDUBTKDZPLC-UHFFFAOYSA-N

物化性质

• 熔点：
  110 °C
• 沸点：
  301.8±27.0 °C(Predicted)
• 密度：
  1.406±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  57.8
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-chloro-N-methyl-5-nitro-aniline 在 氨 、 水 作用下， 生成 N2-甲基-4-硝基-1,2-苯二胺
  参考文献：
  名称：

  CXLIX。—苯并咪唑的甲基化

  摘要：

  DOI：

  10.1039/jr9310001143
• 作为产物：
  描述：

  toluene-4-sulfonic acid-(2-chloro-5-nitro-anilide) 在 potassium carbonate 作用下， 以 丙酮 为溶剂， 生成 2-chloro-N-methyl-5-nitro-aniline
  参考文献：
  名称：

  Synthesis of quinoxaline derivatives from substituted acetanilides through intramolecular quaternization reactions

  摘要：

  对2-二烷基氨基-2′-卤烷基和2-氯-2′-(二烷基氨基)乙酰苯胺环化为喹喏啉衍生物的反应进行了详细研究。根据取代基和实验条件，这些反应通过分子内芳香族亲核或脂肪族亲核取代反应进行，分别生成3-氧喹喏啉盐，或者在消除烷基氯之后生成喹喏啉-2-酮。还描述了一些关于芳基卤化物与三氟氨基化物的分子内季铵化的新案例。

  DOI：

  10.1039/b109725c

文献信息

• Aryl triazines as LPAAT-SS inhibitors and uses thereof
  申请人：Cell Therapeutics, Inc.

  公开号：US20030153570A1

  公开（公告）日：2003-08-14

  The invention relates to aryl triazines and uses thereof, including to inhibit lysophosphatidic acid acyltransferase &bgr; (LPAAT-&bgr;) activity and/or proliferation of cells such as tumor cells.

  本发明涉及芳基三嗪及其用途，包括用于抑制溶血磷脂酸酰基转移酶β（LPAAT-β）活性和/或诸如肿瘤细胞的细胞增殖。
• Competition between Nucleophilic Substitution of Halogen (S_NAr) versus Substitution of Hydrogen (S_NArH)-A Mass Spectrometry and Computational Study
  作者：Kacper Błaziak、Mieczysław Mąkosza、Witold Danikiewicz

  DOI：10.1002/chem.201406542

  日期：2015.4.13

  ylacetamide carbanions (X=H, F, Cl) has been studied using negative ion electrospray mass spectrometry ((−)ESI‐MS) technique and modelled computationally. It was proven that all three anions form cyclic σH adducts, which undergo elimination of water. In the case of X=F, formation of the σF adduct, leading to SNAr reaction, was a competing process. This is the first proof that also in the gas phase

  使用负离子电喷雾质谱（（-）ESI-MS）研究了N-（2-X--5-硝基苯基）-N-甲基乙酰胺碳负离子（X = H，F，Cl）的分子内气相反应机理）技术并进行计算建模。据证实，这三个阴离子形成环状σ ^ h加合物，其经历消除水。在X = F，形成σ的情况下˚F加合物，导致至S Ñ的Ar反应，是一个竞争的过程。这是第一个证明，在气相中H形成加合物的过程也比X进行得快。加合物，并且只有当X = F时，这两个过程的速率才具有可比性。实验结果与量子化学计算完全吻合。
• Substituted bis-(4-aminophenyl)-sulfones
  申请人：Dr. Karl Thomae GmbH

  公开号：US04829058A1

  公开（公告）日：1989-05-09

  Disclosed are substituted bis(4-aminophenyl)-sulfones of general formula ##STR1## wherein R.sub.1 is hydrogen, alkyl or cycloalkyl; group, R.sub.2 is hydrogen or C.sub.1 -C.sub.3 alkyl, R.sub.3 is nitrile, C.sub.1 -C.sub.3 alkylaminocarbonyl, di C.sub.1 -C.sub.3 alkylaminocarbonyl, C.sub.3 -C.sub.7 N-cycloalkyl-C.sub.1 -C.sub.3 alkylaminocarbonyl C.sub.1 -C.sub.3 alkylamino, C.sub.1 -C.sub.3, di alkylaminocarbonyl alkoxy, alkylaminosulfonyl, di C.sub.1 -C.sub.3 alkylaminono, diC.sub.1 -C.sub.3 alkylaminosulfonyl, hydroxy C.sub.1 -C.sub.3 alkyl, C.sub.1 -C.sub.3 alkylcarbonyl, amino C.sub.1 -C.sub.3 alkyl or C.sub.1 -C.sub.3 alkoxy C.sub.1 -C.sub.3 alkyl group or, when R.sub.1 and R.sub.2 are each hydrogen, R.sub.3 can be hydroxy, hydroxycarbonyl C.sub.1 -C.sub.3 alkoxy or di C.sub.1 -C.sub.3 aminocarbonylalkoxy; or, when R.sub.1 is C.sub.1 -C.sub.3 alkyl or C.sub.1 -C.sub.3 cycloalkyl and R.sub.2 is hydrogen or C.sub.1 -C.sub.3 alkyl, R.sub.3 can also be halogen, trifluoromethyl, nitro, amino, aminosulfonyl, aminocarbonyl, C.sub.1 -C.sub.3 alkyl, carboxy or C.sub.1 -C.sub.3 alkoxycarbonyl; and R.sub.4 is hydrogen or, when R.sub.1 and R.sub.2 are each hydrogen and R.sub.3 is halogen or hydroxy, R.sub.4 can also be halogen, hydroxy or C.sub.1 -C.sub.3 alkoxy; or a nontoxic, pharmaceutically acceptable salt thereof. Also disclosed are pharmaceutical compositions comprising such compounds alone and in combination with dihydrofolic acid-reductase inhibitors. The compounds and compositions are useful for their inhibiting effect on bacteria, mycobacteria and plasmodia.

  揭示了通式##STR1##中的取代双(4-氨基苯基)-砜，其中R.sub.1是氢、烷基或环烷基；基团，R.sub.2是氢或C.sub.1 -C.sub.3烷基，R.sub.3是腈基、C.sub.1 -C.sub.3烷基氨基甲酰基、二C.sub.1 -C.sub.3烷基氨基甲酰基、C.sub.3 -C.sub.7-N-环烷基-C.sub.1 -C.sub.3烷基氨基甲酰基、C.sub.1 -C.sub.3烷基氨基、C.sub.1 -C.sub.3，二烷基氨基甲酰基烷氧基、烷基氨基磺酰基、二C.sub.1 -C.sub.3烷基氨基磺酰基、羟基C.sub.1 -C.sub.3烷基、C.sub.1 -C.sub.3烷基羰基、氨基C.sub.1 -C.sub.3烷基或C.sub.1 -C.sub.3烷氧基烷基基团或者，当R.sub.1和R.sub.2分别为氢时，R.sub.3可以是羟基、羟基羰基C.sub.1 -C.sub.3烷氧基或二C.sub.1 -C.sub.3氨基甲酰氧基；或者，当R.sub.1为C.sub.1 -C.sub.3烷基或C.sub.1 -C.sub.3环烷基且R.sub.2为氢或C.sub.1 -C.sub.3烷基时，R.sub.3还可以是卤素、三氟甲基、硝基、氨基、氨基磺酰基、氨基甲酰基、C.sub.1 -C.sub.3烷基、羧基或C.sub.1 -C.sub.3烷氧羰基；以及R.sub.4是氢或者，当R.sub.1和R.sub.2分别为氢且R.sub.3为卤素或羟基时，R.sub.4还可以是卤素、羟基或C.sub.1 -C.sub.3烷氧基；或其无毒的、药学上可接受的盐。还揭示了包含这种化合物的药物组合物，单独使用或与二氢叶酸还原酶抑制剂结合。这些化合物和组合物对细菌、分枝杆菌和疟原虫的抑制作用很有用。
• Anti-bacterial compositions comprising a substituted
  申请人：Dr. Karl Thomae GmbH

  公开号：US05084449A1

  公开（公告）日：1992-01-28

  Disclosed are substituted bis(4-aminophenyl-sulfonees of general formula ##STR1## wherein R.sub.1 is hydrogen, alkyl or cycloalkyl; group, R.sub.2 is hydrogen or C.sub.1 -C.sub.3 alkyl, R.sub.3 is nitrile, C.sub.1 -C.sub.3 alkylaminocarbonyl, di C.sub.1 -C.sub.3 alkylaminocarbonyl, C.sub.3 -C.sub.7 N-cycloalkyl-C.sub.1 -C.sub.3 alkylaminocarbonyl C.sub.1 -C.sub.3 alkylamino, C.sub.1 -C.sub.3, di alkylaminocarbonyl alkoxy, alkylaminosulfonyl, di C.sub.1 -C.sub.3 alkylaminono, diC.sub.1 -C.sub.3 alkylaminosulfonyl, hydroxy C.sub.1 -C.sub.3 alkyl, C.sub.1 -C.sub.3 alkylcarbonyl, amino C.sub.1 -C.sub.3 alkyl or C.sub.1 -C.sub.3 alkoxy C.sub.1 -C.sub.3 alkyl group or, when R.sub.1 and R.sub.2 are each hydrogen, R.sub.3 can be hydroxy, hydroxycarbonyl C.sub.1 -C.sub.3 alkoxy or di C.sub.1 -C.sub.3 aminocarbonylalkoxy; or, when R.sub.1 is C.sub.1 -C.sub.3 alkyl or C.sub.1 -C.sub.3 cycloalkyl and R.sub.2 is hydrogen or C.sub.1 -C.sub.3 alkyl, R.sub.3 can also be halogen, trifluoromethyl, nitro, amino, aminosulfonyl, aminocarbonyl, C.sub.1 -C.sub.3 alkylo, carboxy or C.sub.1 -C.sub.3 akoxycarbonyl; and R.sub.4 is hydrogen or, when R.sub.1 and R.sub.2 are each hydrogen and R.sub.3 is halogen or hydroxy, R.sub.4 can also be halogen, hydroxy or C.sub.1 -C.sub.3 alkoxy; or a nontoxic, pharmaceutically acceptable salt thereof. Also disclosed are pharmaceutical compositions comprising such compounds alone and in combination with dihydrofolic acid-reductage inhibitors. The compounds and compositions are useful for their inhibiting effect on bacteria, mycobacteria and plasmodia.

  揭示了一种通用式为##STR1##的取代的双(4-氨基苯基-砜)化合物，其中R.sub.1是氢、烷基或环烷基；基团，R.sub.2是氢或C.sub.1-C.sub.3烷基，R.sub.3是腈、C.sub.1-C.sub.3烷基氨基羰基、二C.sub.1-C.sub.3烷基氨基羰基、C.sub.3-C.sub.7 N-环烷基-C.sub.1-C.sub.3烷基氨基羰基、C.sub.1-C.sub.3烷基氨基、C.sub.1-C.sub.3, 二烷基氨基羰基氧基、烷基氨基磺酰基、二C.sub.1-C.sub.3烷基氨基、二C.sub.1-C.sub.3烷基氨基磺酰基、羟基C.sub.1-C.sub.3烷基、C.sub.1-C.sub.3烷基羰基、氨基C.sub.1-C.sub.3烷基或C.sub.1-C.sub.3烷氧基烷基或，当R.sub.1和R.sub.2分别为氢时，R.sub.3可以是羟基、羟基羰基C.sub.1-C.sub.3烷氧基或二C.sub.1-C.sub.3氨基羰基氧基；或者，当R.sub.1为C.sub.1-C.sub.3烷基或C.sub.1-C.sub.3环烷基且R.sub.2为氢或C.sub.1-C.sub.3烷基时，R.sub.3也可以是卤素、三氟甲基、硝基、氨基磺酰基、氨基羰基、C.sub.1-C.sub.3烷氧、羧基或C.sub.1-C.sub.3氧羰基；而R.sub.4是氢或，当R.sub.1和R.sub.2分别为氢且R.sub.3为卤素或羟基时，R.sub.4也可以是卤素、羟基或C.sub.1-C.sub.3烷氧；或其无毒的、药学上可接受的盐。还揭示了包含这种化合物的药物组合物，单独使用或与二氢叶酸还原酶抑制剂结合。这些化合物和组合物对细菌、分枝杆菌和疟原虫的抑制作用具有用处。
• [EN] 6-PHENYL-N-PHENYL-(1,3,5) -TRIAZINE-2,4-DIAMINE DERIVATIVES AND RELATED COMPOUNDS WITH LYSOPHPHOSPHATIDIC ACID ACYLTRANSFERASE BETA (LPAAT-BETA) INHIBITORY ACTIVITY FOR USE IN THE TREATMENT OF CANCER<br/>[FR] DERIVES DE 6-PHENYL-N-PHENYL-(1,3,5)-TRIAZINE-2,4-DIAMINE ET COMPOSES APPARENTES AYANT UN EFFET INHIBITEUR DE L'ACIDE LYSOPHOSPHATIDIQUE ACYLTRANSFERASE BETA (LPAAT-BETA) ET DESTINES A ETRE UTILISES POUR TRAITER LE CANCER
  申请人：CELL THERAPEUTICS INC

  公开号：WO2003037346A1

  公开（公告）日：2003-05-08

  The invention relates to aryl triazines and uses thereof, including to inhibit lysophosphatidic acid acyltransferase β (LPAAT-β) activity and/or proliferation of cells such as tumor cells, where R1-R5 are hydrogen or non-ydrogen substituents, and Q is a heteroatom or heteroatom attached to one or more methylene groups.

  该发明涉及芳基三嗪及其用途，包括抑制溶血磷脂酸酰转移酶β（LPAAT-β）活性和/或细胞增殖，如肿瘤细胞，其中R1-R5是氢或非氢取代基，Q是杂原子或附加在一个或多个亚甲基基团上的杂原子。